Nicolas Dumaz

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8861638/publications.pdf

Version: 2024-02-01

63	3,193	218677	149698
papers	citations	26 h-index	56 g-index

65	65	65	4089
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO Journal, 1999, 18, 7002-7010.	7.8	390
2	Integrating signals between cAMP and the RAS/RAF/MEK/ERK signalling pathways. Based on The Anniversary Prize of the Gesellschaft fur Biochemie und Molekularbiologie Lecture delivered on 5 July 2003 at the Special FEBS Meeting in Brussels. FEBS Journal, 2005, 272, 3491-3504.	4.7	274
3	In Melanoma, RAS Mutations Are Accompanied by Switching Signaling from BRAF to CRAF and Disrupted Cyclic AMP Signaling. Cancer Research, 2006, 66, 9483-9491.	0.9	271
4	Specific UV-induced mutation spectrum in the p53 gene of skin tumors from DNA-repair-deficient xeroderma pigmentosum patients.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 10529-10533.	7.1	263
5	Protein Kinase A Blocks Raf-1 Activity by Stimulating 14-3-3 Binding and Blocking Raf-1 Interaction with Ras. Journal of Biological Chemistry, 2003, 278, 29819-29823.	3.4	224
6	The role of UV-B light in skin carcinogenesis through the analysis of p53 mutations in squamous cell carcinomas of hairless mice. Carcinogenesis, 1997, 18, 897-904.	2.8	139
7	The specificity of p53 mutation spectra in sunlight induced human cancers. Journal of Photochemistry and Photobiology B: Biology, 1995, 28, 115-124.	3.8	137
8	Protein kinase CK1 is a p53-threonine 18 kinase which requires prior phosphorylation of serine 15. FEBS Letters, 1999, 463, 312-316.	2.8	119
9	Skin Tumors Induced by Sorafenib; Paradoxic RASâ€“RAF Pathway Activation and Oncogenic Mutations of HRAS, TP53, and TGFBR1. Clinical Cancer Research, 2012, 18, 263-272.	7.0	119
10	Can we predict solar ultraviolet radiation as the causal event in human tumours by analysing the mutation spectra of the p53 gene?. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1994, 307, 375-386.	1.0	92
11	ERK and PDE4 cooperate to induce RAF isoform switching in melanoma. Nature Structural and Molecular Biology, 2011, 18, 584-591.	8.2	81
12	Cyclic AMP Blocks Cell Growth through Raf-1-Dependent and Raf-1-Independent Mechanisms. Molecular and Cellular Biology, 2002, 22, 3717-3728.	2.3	71
13	c-Kit mutants require hypoxia-inducible factor 1Î± to transform melanocytes. Oncogene, 2010, 29, 227-236.	5.9	70
14	Critical roles for the serine 20, but not the serine 15, phosphorylation site and for the polyproline domain in regulating p53 turnover. Biochemical Journal, 2001, 359, 459-464.	3.7	60
15	Prolonged p53 protein accumulation in trichothiodystrophy fibroblasts dependent on unrepaired pyrimidine dimers on the transcribed strands of cellular genes. Molecular Carcinogenesis, 1997, 20, 340-347.	2.7	59
16	PARKINInactivation Links Parkinsonâ€™s Disease to Melanoma. Journal of the National Cancer Institute, 2016, 108, djv340.	6.3	56
17	Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations. Human Pathology, 2013, 44, 1902-1911.	2.0	54
18	TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation. Oncotarget, 2016, 7, 53127-53136.	1.8	54

#	Article	IF	Citations
19	Critical roles for the serine 20, but not the serine 15, phosphorylation site and for the polyproline domain in regulating p53 turnover. Biochemical Journal, 2001, 359, 459.	3.7	53
20	STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network. Journal of Investigative Dermatology, 2018, 138, 58-67.	0.7	47
21	Atypical BRAF and NRAS Mutations in Mucosal Melanoma. Cancers, 2019, 11, 1133.	3.7	47
22	The role of RICTOR downstream of receptor tyrosine kinase in cancers. Molecular Cancer, 2018, 17, 39.	19.2	42
23	Phosphorylation of murine double minute clone 2 (MDM2) protein at serine-267 by protein kinase CK2 in vitro and in cultured cells. Biochemical Journal, 2001, 355, 347-356.	3.7	37
24	Mechanism of RAF isoform switching induced by oncogenic RAS in melanoma. Small GTPases, 2011, 2, 289-292.	1.6	30
25	Phosphorylation of murine double minute clone 2 (MDM2) protein at serine-267 by protein kinase CK2 in vitro and in cultured cells. Biochemical Journal, 2001, 355, 347.	3.7	27
26	RICTOR involvement in the PI3K/AKT pathway regulation in melanocytes and melanoma. Oncotarget, 2015, 6, 28120-28131.	1.8	26
27	Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles. Oncotarget, 2016, 7, 26628-26652.	1.8	25
28	PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma. Oncogene, 2017, 36, 3252-3262.	5.9	25
29	Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma. Current Opinion in Oncology, 2020, 32, 79-84.	2.4	25
30	Recovery of the normal p53 response after UV treatment in DNA repair- deficient fibroblasts by retroviral-mediated correction with the XPD gene. Carcinogenesis, 1998, 19, 1701-1704.	2.8	23
31	Recent discoveries in the genetics of melanoma and their therapeutic implications. Archivum Immunologiae Et Therapiae Experimentalis, 2007, 55, 363-372.	2.3	19
32	A Large French Case-Control Study Emphasizes the Role of RareMc1RVariants in Melanoma Risk. BioMed Research International, 2014, 2014, 1-10.	1.9	19
33	Raf Phosphorylation. Molecular Cell, 2005, 17, 164-166.	9.7	17
34	Mutations causing acrodysostosis-2 facilitate activation of phosphodiesterase 4D3. Human Molecular Genetics, 2017, 26, 3883-3894.	2.9	17
35	Inhibition of the Proprotein Convertases Represses the Invasiveness of Human Primary Melanoma Cells with Altered p53, CDKN2A and N-Ras Genes. PLoS ONE, 2010, 5, e9992.	2.5	16
36	Large expert-curated database for benchmarking document similarity detection in biomedical literature search. Database: the Journal of Biological Databases and Curation, 2019, 2019, .	3.0	15

#	Article	IF	Citations
37	Modulation of signaling through GPCR-cAMP-PKA pathways by PDE4 depends on stimulus intensity: Possible implications for the pathogenesis of acrodysostosis without hormone resistance. Molecular and Cellular Endocrinology, 2017, 442, 1-11.	3.2	13
38	RASA1 loss in a BRAF-mutated Langerhans cell sarcoma: a mechanism of resistance to BRAF inhibitor. Annals of Oncology, 2019, 30, 1170-1172.	1.2	12
39	A targeted genomic alteration analysis predicts survival of melanoma patients under BRAF inhibitors. Oncotarget, 2019, 10, 1669-1687.	1.8	12
40	Validation of a preclinical model for assessment of drug efficacy in melanoma. Oncotarget, 2016, 7, 13069-13081.	1.8	12
41	Phosphorylation of murine p53, but not human p53, by MAP kinase in vitro and in cultured cells highlights species-dependent variation in post-translational modification. Oncogene, 1999, 18, 7602-7607.	5.9	11
42	Driver KIT mutations in melanoma cluster in four hotspots. Melanoma Research, 2015, 25, 88-90.	1.2	11
43	Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care. Cancers, 2019, 11, 1203.	3.7	10
44	RICTOR Affects Melanoma Tumorigenesis and Its Resistance to Targeted Therapy. Biomedicines, 2021, 9, 1498.	3.2	10
45	New perspectives on targeting RAF, MEK and ERK in melanoma. Current Opinion in Oncology, 2021, 33, 120-126.	2.4	9
46	Mechanisms of resistance and predictive biomarkers of response to targeted therapies and immunotherapies in metastatic melanoma. Current Opinion in Oncology, 2020, 32, 91-97.	2.4	7
47	FGF2 Induces Resistance to Nilotinib through MAPK Pathway Activation in KIT Mutated Melanoma. Cancers, 2020, 12, 1062.	3.7	7
48	Genetic variation at <scp>KIT</scp> locus may predispose to melanoma. Pigment Cell and Melanoma Research, 2013, 26, 88-96.	3.3	5
49	Hypoxia and MITF regulate KIT oncogenic properties in melanocytes. Oncogene, 2016, 35, 5070-5077.	5.9	5
50	Novel treatment strategy for NRAS-mutated melanoma through a selective inhibitor of CD147/VEGFR-2 interaction. Oncogene, 2022, 41, 2254-2264.	5.9	5
51	A New KIT Mutation (N505I) in Acral Melanoma Confers Constitutive Signaling, Favors Tumorigenic Properties, and Is Sensitive to Imatinib. Journal of Investigative Dermatology, 2014, 134, 1473-1476.	0.7	4
52	Phase II multicentric uncontrolled national trial assessing the efficacy of nilotinib in the treatment of advanced melanomas with c-KIT mutation or amplification.. Journal of Clinical Oncology, 2014, 32, 9032-9032.	1.6	4
53	Mitogen-activated protein kinase blockade in melanoma: intermittent versus continuous therapy, from preclinical to clinical data. Current Opinion in Oncology, 2021, 33, 127-132.	2.4	4
54	A Melanoma-Tailored Next-Generation Sequencing Panel Coupled with a Comprehensive Analysis to Improve Routine Melanoma Genotyping. Targeted Oncology, 2020, 15, 759-771.	3.6	2

#	Article	IF	Citations
55	Association of Vemurafenib and Pipobroman Enhances BRAF-CRAF Dimerization in Squamous Cell Carcinoma. Journal of Investigative Dermatology, 2016, 136, 1302-1305.	0.7	1
56	533 PDE4D is a therapeutic target in melanoma. Journal of Investigative Dermatology, 2017, 137, S283.	0.7	1
57	Vismodegib resistant mutations are not selected in multifocal relapses of locally advanced basal cell carcinoma after vismodegib discontinuation. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e422-e424.	2.4	1
58	Phase II multicentric uncontrolled national trial assessing the efficacy of nilotinib in the treatment of advanced melanomas with c-KIT mutation or amplification: Results of the pharmacodynamic study.. Journal of Clinical Oncology, 2015, 33, e20062-e20062.	1.6	1
59	130 INVITED TKI's, BRAF Inhibitors and the Problem of New Toxicities Such as Keratoacanthoma and Induction of Invasive SCC. European Journal of Cancer, 2011, 47, S32.	2.8	0
60	A targeted genomic analysis uncovered a large spectrum of acquired resistance mechanisms to BRAF inhibitor therapy in metastatic melanoma patients. Annals of Oncology, 2018, 29, iii25-iii26.	1.2	0
61	490 The role of PDE4D in resistance to targeted therapy in melanoma. Journal of Investigative Dermatology, 2019, 139, S299.	0.7	0
62	Abstract 2341: The Subtilisin-like proprotein convertases blockade inhibits the invasiveness of human primary melanoma with alteredP53,CDKN2AandN-Rasgenes. , 2010, , .		0
63	SMO mutations do not seem to drive multifocal relapse of locally advanced basal cell carcinoma after vismodegib discontinuation.. Journal of Clinical Oncology, 2018, 36, e21559-e21559.	1.6	0